Group 1 Pulmonary arterial hypertension ‐ PDE5i leads to higher improvement in WHO functional class compared with placebo (high certainty).
Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in improvement in WHO functional class compared with ERA (moderate certainty).
Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in improvement in WHO functional class compared with placebo, on combination therapy (moderate certainty).
Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i probably leads to higher improvement in WHO functional class compared with placebo (moderate certainty).
Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i showed no clear difference in improvement in WHO functional class compared with placebo (low certainty).
Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i may leads to higher improvement in WHO functional class compared with placebo (low certainty).
Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i probably leads to lower improvement in WHO functional class compared with placebo (moderate certainty).